Conceptus Phase III STOP Trial Designed To Show Clinical And Cost Benefit
This article was originally published in The Gray Sheet
Executive SummaryConceptus intends to secure third-party reimbursement by examining cost-effectiveness endpoints as a part of Phase III pivotal studies of the firm's STOP non-surgical permanent female contraceptive device.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.